The aim of the trial was therefore amended: evaluation of panitumumab would now focus on patients with KRAS wild-type tumours, with quantification of treatment benefit and evaluation of further biomarkers in this selected population, rather than in an unselected population. This evidence concerns the gene KRAS and neoplasm.